Furthermore, in mouse models of gastric and breast cancer, β‐adrenergic activation has been shown to induce resistance to HER2‐targeted therapy with trastuzumab, with clinical observations supporting these findings by linking tumor expression of β‐ARs to reduced efficacy of trastuzumab in breast cancer patients.271, 272. This evidence concerns the gene CTBP1 and breast carcinoma.